⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CCCC News
C4 Therapeutics, Inc.
Form 8-K
sec.gov
CCCC
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
CCCC
Form 8-K
sec.gov
CCCC
Form 8-K
sec.gov
CCCC
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
globenewswire.com
CCCC
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
globenewswire.com
CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CCCC
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
prnewswire.com
IOVA
VIR
CCCC
ONCY
IMCR
Form 8-K
sec.gov
CCCC
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
globenewswire.com
CCCC